

# News Release



## NeoMed Innovation IV - new specialist healthcare and life sciences fund

Oslo, 30. December 2005:

NeoMed Management announced that it has held the final closing of NeoMed Innovation IV LP, a Jersey based healthcare and life sciences venture capital fund. The fund has a total of €104 million (US\$ 124 million) in committed capital. Investors are fund-of-funds, institutional and private investors based in the UK, Sweden, Norway, Saudi Arabia and Switzerland.

Erik Amble, founding partner of NeoMed Management said: "We are pleased that NeoMed Innovation IV has reached its target size of €100 million in a busy private equity fund raising environment in 2005. NeoMed is now well positioned as a leading European based venture capital firm specializing in the healthcare and life sciences industry."

NeoMed invests in innovative, emerging healthcare and life sciences companies in Continental Europe, Scandinavia and to a lesser extent in the UK and the US. From offices in Oslo and Geneva, NeoMed acts as a lead or co-lead investor in companies located along the axis from Scandinavia to Switzerland.

NeoMed Innovation IV has recently completed due diligence and made its first investment in Endosense SA, a Swiss medical instrument company. Endosense is developing pressure guided catheters for the treatment of atrial fibrillation. The investment is made in syndication with 3i of the UK.

NeoMed's other recent portfolio investments in earlier funds include Axovan, Kuros BioSurgery and Thommen Medical in Switzerland, Clavis Pharma in Norway, Paion in Germany. NeoMed's US investments are mostly syndicated investments with leading local venture capitalists and include Aderis, Pharmion, Volcano Therapeutics and Xanthus.

---ooOoo---

- ◆ NeoMed Management is a Jersey domiciled venture capital fund manager concentrating on the international healthcare and life sciences industry from offices in Oslo, Geneva and New York. NeoMed Management (Jersey) Limited is owned by its four partners, Erik Amble (Swiss), Carl Christian Gilhuus-Moe (Norwegian), Claudio Nessi (Swiss), Tom Pike (Norwegian, British), and Höegh Capital Partners, based in the UK. Höegh Capital Partners acts as financial advisor to the investment interests of the Höegh family and its professional partners.
- ◆ NeoMed Management has raised four specialized healthcare and life science investment funds:
  - NeoMed Investments Ltd. (NeoMed I), formed in 1997 to invest in private and public companies,
  - NeoMed Innovation ASA (NeoMed II), a 1998 vintage venture capital fund,
  - NeoMed Innovation III L P (NeoMed III), a 2001 vintage venture capital fund and
  - NeoMed Innovation IV LP (NeoMed IV), a 2005 vintage venture capital fund
- Additional information: [www.neomed.net](http://www.neomed.net) or contact  
Oslo: Erik Amble, +47 2254 5940, +47 9226 7187, [eamble@neomed.no](mailto:eamble@neomed.no)  
Geneva: Claudio Nessi, +41 22 312 3333, +41 79 612 6531, [claudio@neomed.ch](mailto:claudio@neomed.ch)